Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiovascular risk.(1) The findings were reported today at the American Diabetes Association's 79th Scientific Sessions in San Francisco.
Nucala (mepolizumab) gains FDA approval for two new self-administration options
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate.
Jeff Settleman, Ph.D., joins Pfizer to lead Oncology Research & Development
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that Jeff Settleman, Ph.D., will join the company as Senior Vice President and Group Head of Oncology Research & Development, leading all early oncology research, from discovery to proof of concept clinical studies. Dr. Settleman, a leader in molecularly targeted cancer therapeutics, the epigenetics of cancer drug resistance, and personalized cancer medicine, will report directly to
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
- Details
- Category: Novartis
Novartis announced results from the landmark COMBI-d and COMBI-v clinical trials, concluding that first-line treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) offers both overall and progression-free long-term survival benefits to patients with unresectable or metastatic BRAF-mutation positive melanoma.
Bristol-Myers Squibb announces post-closing leadership team
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company’s pending merger with Celgene Corporation (NASDAQ:CELG). The company is evolving key aspects of its R&D and Commercialization structure to drive the continued growth of a highly successful marketed portfolio, maximize the six near-term launch opportunities and deliver the value of the combined pipeline,
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
- Details
- Category: Novartis
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer[1].
Merck pioneers new effort to see MS from the inside out
- Details
- Category: Merck Group
Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple Sclerosis International Federation (MSIF) to raise awareness of the 2.3 million people worldwide living with this challenging disease. In support of this year’s World MS Day theme, #MyInvisibleMS, Merck is making MS visible through a variety of initiatives aimed at shining a light on the hidden symptoms of MS.
More Pharma News ...
- Bayer receives U.S. FDA breakthrough therapy designation for copanlisib for the treatment of marginal zone lymphoma
- Amgen joins with community oncology networks for new research collaboration
- Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures
- APRINOIA Therapeutics awarded grant from The Michael J. Fox Foundation for Parkinson's Research
- New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
- Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
- Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents